Nessan Bermingham is a Partner at Khosla Ventures focusing on Life Science investments with a particular emphasis on nucleic acid editing, novel delivery systems, gene & cell therapy, novel target identification and data analytics for drug discovery and development.

Nessan is a serial biotech entrepreneur and investor having founded multiple companies in the Life Sciences space, most notably Intellia Therapeutics, Liberate Bio, NOneBio and Korro Bio. At Intellia, Nessan led the company from concept through partnering deals, multiple financings and an IPO. He served as president and CEO from inception until December 2017.  Nessan has held investment roles at Atlas Venture and Omega Fund Management, where he successfully invested in and managed multiple investments across the United States and Europe. He received his Ph.D. in Molecular Biology from Imperial College London and was a Howard Hughes Associate Fellow at Baylor College of Medicine.